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Suppression of tumorigenic and metastatic
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Summary Metastatic melanoma, compared with other cancers, appears to be unusual because of its low frequency of p53 mutations and
prevalence of wild-type p53 protein in advanced malignancy. Here, we examined the effects of wild-type and mutated p53 (143 Val-Ala) on
tumorigenic and metastatic potential of two human melanoma cell lines. The cell line UISO-MEL-4 contains wild-type p53 and is tumorigenic,
whereas UISO-MEL-6 lacks p53 and produces lung and liver metastasis upon s.c. injection into athymic mice. Our study showed that UISO-
MEL-4 stably transfected with wild-type p53 cDNA driven by cytomegalovirus promoter-enhancer sequences expressed high levels of p53
and p21 and formed s.c. tumours in vivo. Mutated p53 (143 Val-Ala) expression, on the other hand, inhibited tumour growth in 50% of cases
and produced significantly slower growing non-metastatic tumours. Reduced tumour growth involved necrotic as well as apoptotic cell death.
Inhibition of tumour growth was abrogated by the addition of Matrigel (15 mg ml-1). With UISO-MEL-6 cells, stably transfected with mutant
p53, tumour growth was delayed and metastasis was inhibited. In soft agar colony formation assay, both wild-type and mutant p53
transfectants reduced anchorage-independent colony formation in vitro. These data suggest that mutated (143 Val-Ala) p53, which retains
DNA binding and some of the transactivation functions of the wild-type p53 protein, suppresses tumorigenic and metastatic potentials of
human melanoma cell lines in vivo.
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The tumour-suppressor p53 gene has been found to be mutated in
most human malignancies, including tumours of the colon, lung,
breast and liver (Harris, 1991; Levine et al, 1991, 1994; Chang et
al, 1993a, b; Soussie et al, 1994). Many of these tumour cells are
growth arrested when transfected with the wild-type p53 gene
(Baker et al, 1990; Mercer et al, 1990; Casey et al, 1991; Cajot et
al, 1992; Takahashi et al, 1992). The effects of wild-type p53
protein on cell growth include cell cycle arrest at G,/S or G2/M
check points and cell death through apoptosis (Chen et al, 1991;
Marx, 1993; Haffner and Oren, 1995; Gottlieb and Oren, 1996).
The growth regulatory functions appeared to be mediated by the
interaction of p53 protein with specific DNA sequences, which
may allow regulation oftranscription of a set of genes involved in
growth and apoptotic cell death (Kastan et al, 1992; Wu et al,
1993; Miyashita et al, 1994; Smith et al, 1994). Important genes
that are direct targets of p53 include p21/Wafl, which encodes a
potent inhibitor of the cyclin-dependent kinases (El Diery et al,
1993, 1994; Harper et al, 1993; Xiong et al, 1993), the growth
arrest and DNA damage-inducible gene, GADD45 (Kastan et al,
1992; Smith et al, 1994), and the MDM2 gene, which antagonizes
the activity ofp53 (Barak et al, 1993; Juven et al, 1993). The DNA
binding and transcriptional activity of p53 protein are lost upon
specific mutations in the gene (Zambetti and Levine, 1993).
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Metastatic melanoma, compared with other cancers, appears to
be unusual because of its low frequency of p53 mutations and
prevalence of wild-type p53 protein in advanced malignancy
(Volkenandt et al, 1991; Castresana, 1993; Greenblatt et al, 1994;
Lu and Kerbel, 1994; Montano et al, 1994; Rauth et al, 1993a).
Several studies, including ours, have reported a much higher level
of p53 (2- to 20-fold), mostly wild type, in metastatic melanoma
compared with normal melanocytes (Rauth et al, 1993a; Jiang et
al, 1995). A high level of wild-type p53 has also been detected at
the advanced stage of melanoma in Matrigel-assisted melanoma
progression model in athymic mice (Jiang et al, 1995). Here, we
examined the effects of wild-type and mutated (143 Val-Ala) p53
on tumorigenic and metastatic potentials of two human melanoma
cell lines. The cell line UISO-MEL-4 contains wild-type p53 and
is tumorigenic, whereas UISO-MEL-6 lacks p53 and is metastatic
upon s.c. injection into athymic mice (Rauth et al, 1993a, 1994,
1997). We report that UISO-MEL-4 melanoma cells, stably trans-
fected with wild-type p53 expression vector, expressed high levels
of p53 and p21 and produced s.c. tumours in vivo as the vector-
transfected or parental cells. Mutated p53 (143 Val-Ala) transfec-
tants expressing very high level ofp53 protein, on the other hand,
inhibited tumour growth in 50% of cases and produced non-
metastatic tumours in the rest. Inhibition of tumour growth
involved necrotic as well as apoptotic cell death. Inhibition of
tumour growth was abrogated by the addition of Matrigel. These
data suggest that the protein encoded by the mutant (143 Val-Ala)
p53 gene, which retains DNA binding and some of the transcrip-
tional regulatory properties of wild-type p53 (Zhang et al, 1993;
Friedlander et al, 1996), suppresses tumorigenic and metastatic
potentials ofhuman melanoma cell lines in vivo.
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MATERIALS AND METHODS
Cells and media
The human melanoma cell lines UISO-MEL-4, UISO-MEL-6 are
derived from biopsies obtained from patients with metastatic
melanoma (Rauth et al, 1994). Cells were maintained in MEM-H
[minimum essential medium with Hanks' balanced salt solution
(Gibco, Grand Island, NY, USA)] containing fetal calf serum
(2%), L-glutamine (1%), non-essential amino acids and penicillin-
streptomycin (0.2%).
Plasmids and transfection experiments
The human wild-type p53 expression plasmid pC53-SN3,
mutant p53 plasmid pC53-SCX3 and the expression vector
pCMVNeoBam without p53 cDNA, originally constructed by Bert
Vogelstein (Baker et al, 1990), were used in our studies. The p53
expression plasmids contain wild-type or mutant (143 Val-Ala)
p53 cDNA sequences under the control of cytomegalovirus
(CMV) promoter-enhancer sequences. To isolate cells stably
transfected with p53 expression plasmids or the expression vector,
UISO-MEL-4 cells were co-transfected with plasmids pC53-SN3
or pC53-SCX3 and PIRVGalNeo as described previously (Rauth
et al, 1997). Three days after transfection, the cells were subcul-
tured in the presence of 1 mg ml G418 (Sigma Chemical). The
selective media with G418 was replaced every 3 days, and
colonies that appeared after 10-14 days were pooled and sub-
cultured for further analysis.
Western blot analysis
For Western blot analysis, transfected cells were lysed in lysis
buffer containing 50 mm Tris (pH 8.0), 250 mm sodium chloride
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Figure 1 Western blot analysis for p53 protein expression in UISO-MEL-4
(A) and UISO-MEL-6 (B) melanoma cells stably transfected with wild-type or
mutant p53. The stable transfectants with wild-type p53 were designated as
MEL-4WP and had the mutants MEL-4MP or MEL-6MP. p53 protein level
was analysed using p53 monoclonal antibody Ab-2 (PAb1801) from
Oncogene Science. Cell extracts, each containing 150 9g of total protein,
were separated by a SDS 12.5% polyacrylamide gel. p53 protein is detected
with 1:200 dilution of p53 monoclonal antibody and chemiluminescence
system (Amersham)
and 0.1% Nonidet p-40 as described previously (Rauth et al,
1997). Cell extracts containing equal amounts of protein (150 gg)
were separated on a SDS 12.5% polyacrylamide gel. Proteins were
transferred electrophoretically to a nitrocellular membrane, and
the p53 proteins in the blot were detected with a 1:200 dilution of
p53 monoclonal antibody Ab-2 (pAbI801, Oncogene Science)
and the enhanced chemiluminescence system (Amersham).
Reverse transcriptase polymerase chain reaction
(RT-PCR) for p53 and p21
p53 and p21 mRNAs in the transfected cells were analysed using
RT-PCR of total cellular RNA as described previously (Rauth et
al, 1993a; 1997). To avoid the plateau effect, PCR reaction condi-
tions were optimized and run for 25 cycles. The sequences of the
primers used to amplify p53 cDNA are spaced 1225 bp apart and
yield full-length cDNA fragment. Primer 1: 5'-AGACTGCCTTC-
CGGGTCACT-3'; primer 2: 5'-GGGAACAAAGAAGTGGA-
GAAT-3' as described previously (Kichina et al, 1996). The
sequences of the primers used to amplify p21 cDNA were
obtained from published sequences (Volkenandt et al, 1991).
Primer 1: 5'-GGATGAGTTGGGAGGAGGCA-3'; primer 2: 5'-
TTGGAGAAGATCATCCGGCG-3'. These primers yield a 224-
bp PCR product. P2-Microglobulin (A2-m) mRNA, used as an
internal control, was also analysed by RT-PCR. The sequences of
the primers used to amplify P2-microglobulin were obtained from
published sequences (Noonan et al, 1990) and yield a 120-bp
cDNA fragment.
Soft agar colony formation assay
Soft agar colony formation assays were performed essentially as
described by Huang et al (1988). An equal number of cells
(1 x 104) from each of the transfectants and parental cells were
seeded in 0.367% agar. After 21 and 28 days of incubation at
37°C, the number ofcolonies was counted.
Assay for tumorigenicity and metastasis
Melanoma cells were harvested from tissue culture andresuspended
in Hanks' balanced salt solution. A total of 1-2 x 106 viable cells in
a0.2-ml volume were injected subcutaneously in either flank in sets
of five mice for each cell line as described (Rauth et al, 1993a).
Three- tofour-week-old Nu/Nu mice, used in ourexperiments, were
obtained from NCI, Frederick, MD, USA. Tumour growth was
determined twice a week by measuring all three diameters [length
(L), width (W) and thickness (7)] ofthe subcutaneous tumour with a
vernier caliper. The tumour volume (expressed in cm3) was calcu-
lated based on the formula length x width x thickness/6 and by
weighing the fresh tumour at the time ofautopsy. When the primary
tumours reached 2 cm in diameter, mice were killed by carbon
dioxide inhalation, and their lungs, livers, kidneys and hearts were
removed and examined for the presence of gross and microscopic
metastasis. The presence of metastatic melanoma in these tissues
was histologically confirmed.
Histological and immunocytochemical analysis
For histology, primary and metastatic tumour tissues were fixed in
10% formalin, washed in phosphate-buffered saline (PBS), dehy-
drated in ethanol, and then embedded in paraffin. Sections were
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Figure 3 Immunostaining of p53 protein in UISO-MEL-6 (A) and its mutant
p53 transfectants (B). Cells were grown and analysed for p53 protein as
described in Figure 2
Figure 2 Immunocytochemical staining of p53 protein in UISO-MEL-4 (A)
stably transfected with wild-type (B) and mutated p53 (C). Cells grown on
coverslips were analysed for p53 protein using the labelled
streptavidin-biotin (LSAB) staining kit (Oncogene Science) and antibody p53
(Ab-6) (Oncogene Science) specific for human wild-type and mutant p53.
MAb p3, a non-specific IgGK prepared from BALB/C mouse myeloma
p3-X63-88, was used to monitor non-specific binding in the analysis
stained with haematoxylin and eosin. Immunocytochemical
analysis of the cells was performed using the streptavidin biotin
(LSAB) technique, based on the indirect immunoperoxidase
method as described previously (Rauth et al, 1993a). The LSAB kit
was purchased from Dako, CA, USA, and antibody p53 (Ab-6),
specific for human wild-type and mutant p53 was purchased from
Oncogene Science. MAb p3, a non-specific IgGk prepared from
BALB/c mouse myeloma p3-X63-88 (Rauth et al, 1993b), was
used to monitor non-specific binding in the analysis. Briefly, cells
grown on coverslips were treated with 3% hydrogen peroxide, to
inhibit endogenous peroxidase activity, and then with blocking
serum (non-immune goat serum). Cells were then incubated with
primary antibody, p53 Ab-6, after removing the blocking serum.
The link antibody (biotynylated anti-mouse and anti-rabbit
immunoglobulin) was then overlaid, followed by PBS wash. Cells
were next exposed to streptavidin conjugated to peroxidase,
followed by hydrogen peroxide and AEC (3-amino-9-ethylcar-
bazole, Dako) additions and counter staining with haematoxylin.
RESULTS
Expression of wild-type or mutant (143 Val-Ala) p53
genes in UISO MEL-4 and UISO-MEL-6 human
melanoma cell lines
To examine the effects of p53 on tumorigenic and metastatic
properties of melanoma cells, we chose to transfect two human
melanoma cell lines (UISO-MEL-6 and UISO-MEL-4) that either
lack or contain wild-type p53. Using the calcium phosphate
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Figure 4 Expression of p53 mRNA in UISO-MEL-4 stable transfectants.
p53 mRNA was analysed by reverse transcriptase polymerase chain reaction
(RT-PCR). The sequences of the primers used to amplify p53cDNA were
spaced 1225 bp apart spanning the entire coding region of the gene. 2-
microglobulin mRNA, used as an internal control, was also analysed by RT-
PCR using primers that yield a 120-bp product. A 10-ill RT-PCR mix was
loaded on 2.5% agarose gel
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Figure 5 Expression of p21 mRNA in UISO-MEL-4 human melanoma cells
stably transfected with wild-type and mutant p53. p21 mRNA was analysed
by reverse transcription and polymerase chain reaction (RT-PCR) using
primers that give rise to 224-bp p21 cDNA fragment. P2-microglobulin mRNA,
used as an internal control, was also analysed by RT-PCR using primers that
yield a 120-bp product
precipitation procedure, cells were transfected with wild-type or
mutant (143 Val-Ala) p53 cDNA containing expression vector, as
described previously (Rauth et al, 1997). The (143 Val-Ala) p53
mutant has been shown to retain DNA binding and some of the
transactivation function of wild-type p53 (Zhang et al, 1993;
Friedlander et al, 1996). As a control, the expression vector
pCMVNeoBam without p53 insert was also transfected into the
cells under the same conditions. Three days after transfection, the
cells were subcultured in the presence of 1 mg ml-' G418. The
colonies that appeared after 10-14 days were pooled and expanded
so that numerous colonies could be assessed simultaneously.
Consistent with the premise that overexpression of wild-type p53
results in a selective disadvantage compared with mutant p53,
we observed a lower number of colonies with wild-type p53
compared with that obtained with mutated p53 in the case of
MEL-4 cells. In the case of UISO-MEL-6, which is p53 negative,
none ofthe wild-type p53 transfectants survived. The transfectants
with wild-type p53 were designated as MEL-4 WP and had the
mutants MEL-4 MP or MEL-6MP. The transfectants with expres-
sion vector were designated as MEL-4 NP or MEL-6NP
The stably transfected cells were then analysed for p53 protein
expression using Western blot hybridization with p53 monoclonal
antibody Ab-2 (PAbi801, Oncogene Science). As shown in Figure
IA, high levels of p53 proteins were detected in MEL-4 WP and
MEL-4 MP compared with parental MEL-4 cells. The MEL-4 MP
cells expressed a very high level of p53 protein, and this accumu-
lation could be due to stabilization of the mutant p53 by complex
formation with wild-type p53 or other proteins (Zambetti et al,
1993). Figure lB shows a high level of p53 protein in MEL-6MP
and no p53 in parental MEL-6 cell line. To examine whether the
transfectants express p53 uniformly in level and localization, p53
expression was also analysed immunocytochemically using p53
monoclonal antibody Ab-6 (Oncogene Science). As shown in
Figure 2, a high level of uniform immunostaining, both nuclear
and cytoplasmic, was detected in p53 transfectants of the MEL-4
cell line. Figure 3 shows high level of uniform immunostaining in
MEL-6MP cells.
To determine whether a high level ofp53 expression is not due to
accumulation of the protein but due to transcription from the trans-
fected plasmids, we analysed total cellular RNA from the transfec-
tants using RT-PCR. As shown in Figure 4, MEL-4 WP or MP
expressed a higher level of p53 transcript than parental MEL-4
cells. As an internal control for p53 expression, we analysed P,-m
mRNA levels using RT-PCR. The P2-m gene is ubiquitously
expressed (Morrelo et al, 1990) and is used to monitor the levels of
cDNA in RT-PCR. The P2-m band appears to be similar in intensity
for all cell types and therefore indicates equal RNA loading of all
samples. Taken together, these results show that p53 was expressed
from the transfected plasmids in human melanoma cells.
Expression of the p21 gene is directly induced by wild-type p53
and is an important mediator of p53-dependent tumour growth
suppression (El Diery et al, 1994). To determine whether p53 in
the stable transfectants induced p21 gene expression, p21 mRNA
expression was analysed using RT-PCR. As shown in Figure 5, an
increased level of p21 mRNA was detected in the wild-type p53
transfectants. P2-Microglobulin mRNA, analysed using RT-PCR,
remained unchanged in both wild-type and mutant p53 transfec-
tants. The levels ofp21 protein in the stable transfectants were also
analysed by immunocytochemical analysis using antibody WafI
(Ab-1). A higher level of immunostaining was detected in p53
wild-type transfectants compared with parental MEL-4 (data not
shown), indicating the presence of high levels of p21 protein.
These results show that wild-type p53 expressed from the trans-
fected plasmid induced p21 expression in MEL-4 WP cells.
In vitro growth characteristics of p53 transfectants
The anchorage-dependent growth rates of wild-type and mutant
p53 transfectants were then examined in culture media containing
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Figure 6 In vitro growth rates of UISO-MEL-4 and its derivatives cells. Cells
growing exponentially were plated in triplicate at a density of 1 x 104 cells per
well in multiwell dishes with MEM-E and 10% FBS. At the indicated time
points, cells were trypsinized and counted. The mean numbers from triplicate
wells were plotted against the days. Cultured media were renewed every
3 days
5% fetal calf serum (FCS). As shown in Figure 6, the wild-type
p53 transfected cells had a slightly higher growth rate than did
parental MEL-4 cells or the mutant p53 transfectants.
The anchorage-independent colony formation potential of the
transfectants was also examined by allowing them to grow in
0.367% soft agar in culture media as described in Materials and
methods. As seen in Table 1, both wild-type and mutant p53
transfectants of MEL-4 showed significant reductions in colony-
forming efficiency compared with parental cells (four- to tenfold
less). Colony formation efficiency ofMEL-6 mutant p53 transfec-
tants was also less than parental cells (fourfold less). These data
provide evidence that stably transfected wild-type or mutant p53 in
melanoma cells confers retardation of anchorage-independent
growth in vitro.
Inhibition of tumour growth by mutant (143 Val-Ala) p53
and abrogation by Matrigel
We next asked if stable transfection of wild-type or mutant pS3
cDNA containing pCMVNeo vector into melanoma cells in vitro
would prevent tumour growth and metastasis in vivo in nude mice.
To this end, stable transfectants (1 x 104) were injected subcuta-
neously in two groups of mice (five mice per group) and tumour
growth was measured twice a week. The results are summarized in
Table 2. All animals injected with parental, wild-type p53 transfec-
tants or vector-transfected cells formed tumours, whereas only five
out of ten animals injected with mutant p53 transfectants of
MEL-4 showed tumours. These mutant p53-derived tumours grew
slowly and were significantly smaller than controls. We next tested
whether the addition of Matrigel can stimulate growth of p53
mutant tumours. Matrigel is a reconstituted basement membrane
extract and, when co-injected with tumour cells, permits rapid
tumour growth in nude mice (Kobayashi et al, 1994). Our study
showed that the addition ofMatrigel in a 15 mg ml-' concentration
Table 1 Soft agar colonization assays of p53 transfected melanoma cells
Cell lines Total colonies formeda
21 days 28 days
Fibroblasts 0 0
MEL-4 32 48
MEL-4NP 28 42
MEL-4WP 8 10
MEL-4MP 3 10
MEL-6 28 27
MEL-6MP 6 4
aEqual numbers (1 x 104) of cells of the indicated cell lines were seeded in
the duplicate in 0.367% soft agar as described in Materials and methods.
Total colony numbers in 25 wells were scored after 21 and 28 days.
Table 2 Tumorigenic and metastatic properties of p53 transfected cell lines
Cell Tumour Mean Doubling
time latency time
(%) (days) (weeks)
MEL-4 100 7 1.3
MEL-4 WP 100 7 0.7
MEL-4MP 50 7 2.6
MEL-4MP + 100 7 1.4
Matrigel
MEL-6 100 7 1.4
MEL-6MP 100 28 1.4
About 1-2 x 106 cells from each of the cells lines were injected into either
flanks of 3-4 weeks old Nu/Nu mice. Tumour growth was determined twice a
week. After 8 weeks mice were killed and organs were analysed for
metastatic colonies.
stimulated the tumorigenicity of the cells. The suppressive effect
ofmutated p53 was abrogated, and tumours grew as quickly as the
parental cells. With MEL-6 mutant p53 transfectants, tumour
appearance was delayed and no metastatic colonies were detected
in lung or liver. The parental MEL-6 cells gave rise to metastatic
colonies in 40% of cases, as described previously (Rauth et al,
1994). These data suggest that mutated (143 Val-Ala) p53 in
melanoma cells suppressed certain steps ofthe tumour progression
and that this effect is overcome by Matrigel.
To examine that expressions of the transfected constructs were
not lost in tumour cells during their exposure to the circulatory
system, the s.c. tumours were examined using immunocytochem-
ical analysis. As shown in Figure 7, a high level of p53 protein is
expressed in the primary tumours formed from MEL-4 WP (B) or
MEL-4MP (C) compared with that from MEL-4 cells (A). A high
level of p53 was also detected in MEL-6MP tumours (Figure 8B)
compared with no p53 in MEL-6 tumours (Figure 8A).
We next asked whether there is any change in melanin content in
p53-expressing tumours. Melanin synthesis is the characteristic of
differentiated melanoma cells (Rauth et al, 1990; 1993a; 1997).
The parental MEL-4 and MEL-6 cells are poorly pigmented, and
an increase in melanin content in the transfectants would indicate
presence of differentiated cells. The s.c. tumour tissues were
examined histologically and no significant change in melanin
synthesis was observed. However, p53 mutant tumours demon-
strated a large number of necrotic and apoptotic cells compared
with those obtained from parental or wild-type p53 cells. This may
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Figure 7 Expression of p53 in sections of primary tumours. UISO-MEL-4
(A), wild-type p53 transfectants (B) and mutant p53 transfectants (C).
Tumours were stained immunocytochemically using the monoclonal
antibodies p53 (Ab-6) as described in Figure 2
explain, in part, why the tumours were significantly smaller than
those ofparental orMEL-4 WP cells. Taken together, these studies
showed that stably transfected mutant (143 Val-Ala) p53 inhibited
melanoma growth and progression in vivo.
DISCUSSION
In the present study, we examined the effects of wild-type and
mutant (143 Val-Ala) p53 on tumorigenic and metastatic potentials
of melanoma cell lines. We used p53 expression vectors
containing cytomegalovirus promoter-enhancer sequences and
calcium phosphate-mediated gene transfer approaches. The data
Figure 8 Expression of p53 in sections of primary tumours of UISO-MEL-6
(A) and mutant p53 transfectants (B) analysed immunocytochemically using
the monoclonal antibodies p53 (Ab-6) as described in Figure 2
provide evidence that wild-type p53-transfected cells produced
s.c. tumours as the controls, whereas mutatedp53 inhibited tumour
growth and progression in vivo.
The independent growth rate was consistently inhibited in the
primary tumour formation in the pooled, stable transfectants
expressing mutated p53 in two independent tumorigenicity assays.
In 50% of the inoculated mice, complete inhibition of tumour
growth was observed with MEL-4 cells expressing mutated p53.
In the other 50% of mice, tumours grew at a very slow rate. The
tumour sizes were significantly smaller than tumours produced by
parental MEL-4 cells. The reason why tumours fail to form after
the injection ofarelatively large number oftumour cells is unclear
at present, but it may result from alterations in tumour cell-host
interactions such as angiogenesis. The MEL-6MP-derived s.c.
tumours, unlike parental MEL-6 tumours, did not produce any
metastatic colonies. To produce metastasis, tumour cells must
complete several sequential and selective steps that include inva-
sion, survival in the circulation, arrest in the distant capillary bed,
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extravasion into the distant organ and proliferation (Poste and
Fidler, 1979). The mechanisms by which mutated p53 inhibited
melanoma cells to progress through these sequential steps is
unknown at present. We observed many apoptotic cells in tumours
derived from mutant p53 compared with that in parental or wild-
type p53 tumours. Our Matrigel experiments showed that co-
injection of Matrigel permitted tumour growth from mutant p53
transfectants as rapidly as the parental cells. These data suggest
that expression ofmutated p53 may have inhibited certain steps of
tumour progression of human melanoma cells. It is not surprising
that mutated (143 Val-Ala) p53 inhibits melanoma growth in the
nude mice model. The protein encoded by the p53 mutant (143
Val-Ala) can still bind to the p53 DNA consensus element (Funk et
al, 1992) and can retain some of the transactivation properties of
wild-type p53 (Zhang et al, 1993; Friedlander et al, 1996).
Although we have not tested other p53 mutants, we do not expect
that other mutants would behave as the 143 Val-Ala mutated form
ofp53 in melanoma in vivo. Until now, the 143 Val-Ala p53 muta-
tion has not been detected in melanoma tissues or cell lines.
Further study with more cell lines may suggest the potential ofthis
p53 mutant in clinical implications against melanoma.
Our data also indicated that p53 wild-type cells escaped suppres-
sion of tumour growth. The established role of p53 is to suppress
growth in many cell types through p21 (El Deiry et al, 1994). In our
study, wefound thatthe wild-type p53 transfectants reduced soft agar
colony formation, but failed to suppress tumour growth in vivo. It
waspossible thatthecell line weexaminedcouldhave acquiredpoint
mutation in the wild-type p53 gene during stable transfection. We
considered this unlikely as exogenous wild-type p53 was similar to
endogenous wild-type p53 using several criteria; for example, it
increased p21 expression andinduced CAT gene expression from the
p53-responsive p21 promoter sequences in our preliminary experi-
ments (data not shown). Several studies (including ours) demon-
strated that mutations in the p53 gene are rare in metastatic
melanoma, and wild-type p53 is expressed at a high level
(Volkenandt et al, 1991; Castresana, 1993; Greenblatt et al, 1994; Lu
et al, 1994; Montano et al, 1994; Rauth et al, 1993a). Only one study
(Florence et al, 1995) demonstrated that an increased level of p53
protein does not indicate an increased degree of malignancy in
melanoma, but rather suggests a more favourable disease progres-
sion. In that study, paraffin-embedded primary and metastatic
tumours from patients were analysed. In our experience, analysis of
paraffin-embedded tissues using immunocytochemistry is very sensi-
tive to the procedures used. It is still not clear whether variation in
this study is due to difference in technical procedures used in
immunocytochemical analysis. A recent study demonstrated thatp53
expression increased during evolution from normal melanocytes to
metastatic melanoma (Jiang et al, 1995). The same study also
reported temporal decrease in p53 protein levels with a corre-
sponding increase in p21 levels during growth arrest and terminal
differentiation in human melanoma cells treated with a combination
of recombinant human fibroblasts (IFN-B) and the antileukaemic
compound mezerein (MEZ). In the Matrigel-assisted melanoma
progression model, a high level of p53 was also detected at an
advanced stage of melanoma progression (Jiang et al, 1995). Based
on these studies, it is suggested that melanoma may represent an
unusual malignancy in that it progresses to more advanced stages,
even in the presence ofelevated levels ofwild-type p53. It is still not
known whether ahigh level ofwild-type p53 in metastatic melanoma
is functionally active or not. Loss of normal p53 function could be
reached in a variety of ways, e.g. formation of protein complexes
with viral oncoproteins (e.g. the SV40 T antigen, adenovirus E1B,
papillomavirus E6) and binding to cellular oncogene products (e.g.
MDM2). The other possibility is that downstream genes of p53
are defective in metastatic melanoma. Currently, experiments are
underway in our laboratory to test these possibilities.
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